Ovarian Cancer
Gynecological Cancer Regulatory, Expression Features Found Using Single-Cell Profiling
Researchers explored gene expression, transcription factor, and other regulatory relationships with single-cell data on more than 170,000 ovarian or endometrial tumor cells.
The company is embarking on its own diagnostic plans as it prepares to market its platform for external test development following FDA clearance.
Genoox, Aspira Women's Health Partner to Develop New MDx Technologies
The firms seek to apply AI and machine learning to improve diagnosis and treatment of conditions including ovarian and pelvic diseases.
Qiagen, OncXerna Therapeutics Ink Companion Dx Development, Technology-Licensing Deal
The partners will develop an NGS companion diagnostic for navicixizumab, which OncXerna is developing as a treatment for patients with ovarian cancer.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.